Drug Trial Radar · NCT07357103
Positioning Second-line Therapies for Pneumocystis Jirovecii Pneumonia (PCP Alternatives)
Last checked: Nov 19, 2026Latest source record: Jan 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
416
Planned (sponsor's estimate)
Start
Mar 2026
Primary completion
Mar 2029
Study completion Sep 2029
Sponsor
- Lead sponsor
- McGill University Health Centre/Research Institute of the McGill University Health CentreAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jan 21, 2026
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The usual first treatment for Pneumocystis jirovecii pneumonia (PCP) is an antibiotic called trimethoprim-sulfamethoxazole (TMP-SMX). However, some patients cannot take this medication because of allergies, side effects, or lack of response. This study asks the question: When TMP-SMX cannot be used, which alternative treatment for PCP provides the best balance of effectiveness and safety?
Conditions
- Pneumocystis
- Pneumocystis Infection
- Pneumocystis Carinii Infection
- Pneumocystis Carinii; Infection, Resulting From HIV Disease
- Pneumocystis Jirovecii Pneumonia
- Pneumocystis Jirovecii Infection
- Pneumocystosis Associated With AIDS
- Pneumocystosis; Pneumonia (Etiology)
Interventions
Clindamycin + primaquineDrug
Participants randomized to this intervention will receive clindamycin in combination with primaquine as second-line therapy for the treatment of PCP. This regimen may be used for participants with Severe PCP or mild to moderate PCP in acccordance with protocol-defined disease severity and standard clinical practice.
PentamidineDrug
Participants randomized to this intervention will receive pentamidine, administered intravenously, as second-line therapy for the treatment of PCP in patients with severe disease who are unable to tolerate or have contraindications to trimethoprim-sulfamethoxazole (TMP/SMX)
AtovaquoneDrug
Participants randomized to. this intervention will receive atovaquone, administered orally, as second-line therapy for the treatment of PCP in participants with mild to moderate disease who are unable to tolerate or have contraindications to trimethoprim-sulfamethozaxole (TMP/SMX).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Hierarchical composite outcomeTime frame: Day 30
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.